Novavax Reports Significant Revenue Decline and Net Loss in Q1 2026

Novavax, Inc. reported a significant decline in financial performance for the first quarter of 2026, with total revenue of $139.5 million, down from $666.7 million in the same period of 2025. This decrease of $527.1 million was primarily attributed to a sharp drop in product sales, which fell to $42.2 million from $621.7 million year-over-year. The decline in product sales was largely due to the transition of commercial lead responsibilities for the Nuvaxovid™ COVID-19 vaccine to Sanofi, resulting in reduced direct sales by Novavax. However, licensing, royalties, and other revenue increased to $97.3 million, driven by an upfront payment from Pfizer under a new licensing agreement.

Total expenses for the quarter rose slightly to $154.9 million from $151.1 million in the prior year. The increase was primarily due to higher costs of sales, which included $4.2 million related to losses on firm purchase commitments. Research and development expenses also increased to $95.5 million, reflecting ongoing transition services under the Sanofi collaboration agreement. In contrast, selling, general, and administrative expenses decreased significantly to $28.8 million, down from $48.1 million, as the company implemented cost containment measures.

Novavax reported a net loss of $9.5 million, or $0.06 per share, compared to a net income of $518.6 million, or $3.22 per share, in the first quarter of 2025. The substantial shift from profit to loss was primarily due to the drastic reduction in revenue. The weighted average number of shares outstanding increased to 163.3 million from 161.0 million, reflecting stock issued under incentive programs.

Operationally, Novavax is focusing on strategic partnerships to enhance its product pipeline and revenue potential. The company entered into a licensing agreement with Pfizer in January 2026, which includes an upfront payment of $30 million and potential milestone payments totaling up to $500 million. Additionally, Novavax continues to explore collaborations for its Matrix-M™ adjuvant, with agreements in place with several leading pharmaceutical companies across various therapeutic areas.

Looking ahead, Novavax maintains a positive outlook regarding its liquidity, with $794.9 million in cash, cash equivalents, and marketable securities as of March 31, 2026. The company believes this capital, along with expected revenue from product sales and licensing agreements, will be sufficient to fund operations for at least the next 12 months. However, the ongoing restructuring efforts and the need for additional capital through various financing options remain critical to the company's future operations and growth strategy.